|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang L, Parkin DM, Li L and Chen Y: Time
trends in cancer mortality in China: 1987–1999. Int J Cancer.
106:771–783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pfister DG, Johnson DH, Azzoli CG, Sause
W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT,
et al: American Society of Clinical Oncology treatment of
unresectable non-small-cell lung cancer guideline: Update 2003. J
Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yilmaz A, Damadoglu E, Salturk C, Okur E,
Tuncer LY and Halezeroglu S: Delays in the diagnosis and treatment
of primary lung cancer: Are longer delays associated with advanced
pathological stage? Ups J Med Sci. 113:287–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I: EUROCARE-4 Working
Group: Recent cancer survival in Europe: A 2000–02 period analysis
of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Somaiah N and Simon GR: Molecular targeted
agents and biologic therapies for non-small cell lung cancer. J
Thorac Oncol. 5 12 Suppl 6:S434–S454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donadeu FX, Schauer SN and Sontakke SD:
Involvement of miRNAs in ovarian follicular and luteal development.
J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liwak U, Faye MD and Holcik M: Translation
control in apoptosis. Exp Oncol. 34:218–230. 2012.PubMed/NCBI
|
|
13
|
Rutnam ZJ and Yang BB: The involvement of
microRNAs in malignant transformation. Histol Histopathol.
27:1263–1270. 2012.PubMed/NCBI
|
|
14
|
Rothschild SI: Epigenetic therapy in lung
cancer-role of microRNAs. Front Oncol. 3:1582013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan BZ, Jefferson AM, Baldwin KT,
Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a
tumor suppressor gene in human non-small cell lung carcinomas.
Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng H, Zhang Z, Wang X and Liu D:
Identification of DLC-1 expression and methylation status in
patients with non-small-cell lung cancer. Mol Clin Oncol.
4:249–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Healy KD, Hodgson L, Kim TY, Shutes A,
Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ and Der CJ:
DLC-1 suppresses non-small cell lung cancer growth and invasion by
RhoGAP-dependent and independent mechanisms. Mol Carcinog.
47:326–337. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and
De W: The long non-coding RNA HOTAIR indicates a poor prognosis and
promotes metastasis in non-small cell lung cancer. BMC Cancer.
13:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Chen S, Hang W, Huang H and Ma H:
MiR-95 induces proliferation and chemo- or radioresistance through
directly targeting sorting nexin1 (SNX1) in non-small cell lung
cancer. Biomed Pharmacother. 68:589–595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Zhao Y, Sun S, Liu Z, Zhang Y and
Jiao S: Overexpression of MicroRNA-221 is associated with poor
prognosis in non-small cell lung cancer patients. Tumour Biol.
37:10155–10160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Gong J, Zeng H, Chen N, Huang R,
Huang Y, Nie L, Xu M, Xia J, Zhao F, et al: MicroRNA145 targets
BNIP3 and suppresses prostate cancer progression. Cancer Res.
70:2728–2738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
25
|
Xu T, Liu X, Han L, Shen H, Liu L and Shu
Y: Up-regulation of miR-9 expression as a poor prognostic biomarker
in patients with non-small cell lung cancer. Clin Transl Oncol.
16:469–475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bai Y, Wang YL, Yao WJ, Guo L, Xi HF, Li
SY and Zhao BS: Expression of miR-32 in human non-small cell lung
cancer and its correlation with tumor progression and patient
survival. Int J Clin Exp Pathol. 8:824–829. 2015.PubMed/NCBI
|
|
27
|
Kawano M, Tanaka K, Itonaga I, Iwasaki T
and Tsumura H: MicroRNA-301a promotes cell proliferation via PTEN
targeting in Ewing's sarcoma cells. Int J Oncol. 48:1531–1540.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu Y, Gao W, Zhang C, Wen S, Huangfu H,
Kang J and Wang B: Hsa-miR-301a-3p acts as an oncogene in laryngeal
squamous cell carcinoma via target regulation of Smad4. J Cancer.
6:1260–1275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia X, Zhang K, Cen G, Jiang T, Cao J,
Huang K, Huang C, Zhao Q and Qiu Z: MicroRNA-301a-3p promotes
pancreatic cancer progression via negative regulation of SMAD4.
Oncotarget. 6:21046–21063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang Y, Sun B, Xiang J and Chen Z:
MiR-301a promotes colorectal cancer cell growth and invasion by
directly targeting SOCS6. Cell Physiol Biochem. 35:227–236. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye
ZY and Zhao ZS: Abnormal expression of miR-301a in gastric cancer
associated with progression and poor prognosis. J Surg Oncol.
108:197–202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou P, Jiang W, Wu L, Chang R, Wu K and
Wang Z: miR-301a is a candidate oncogene that targets the homeobox
gene Gax in human hepatocellular carcinoma. Dig Dis Sci.
57:1171–1180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang
X, Dai G and Huang J: Upregulation of miR-301a correlates with poor
prognosis in triple-negative breast cancer. Med Oncol. 31:2832014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma F, Zhang J, Zhong L, Wang L, Liu Y,
Wang Y, Peng L and Guo B: Upregulated microRNA-301a in breast
cancer promotes tumor metastasis by targeting PTEN and activating
Wnt/β-catenin signaling. Gene. 535:191–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Z, Chen LY, Dai HY, Wang P, Gao S and
Wang K: miR-301a promotes pancreatic cancer cell proliferation by
directly inhibiting Bim expression. J Cell Biochem. 113:3229–3235.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang M, Li C, Yu B, Su L, Li J, Ju J, Yu
Y, Gu Q, Zhu Z and Liu B: Overexpressed miR-301a promotes cell
proliferation and invasion by targeting RUNX3 in gastric cancer. J
Gastroenterol. 48:1023–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang W, Zhang T, Jin R, Zhao H, Hu J,
Feng B, Zang L, Zheng M and Wang M: MicroRNA-301a promotes
migration and invasion by targeting TGFBR2 in human colorectal
cancer. J Exp Clin Cancer Res. 33:1132014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Duan G and Feng S: MicroRNA-301a
modulates doxorubicin resistance in osteosarcoma cells by targeting
AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun.
459:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
